<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Drug Investig</journal-id><journal-id journal-id-type="iso-abbrev">Clin Drug Investig</journal-id><journal-title-group><journal-title>Clinical Drug Investigation</journal-title></journal-title-group><issn pub-type="ppub">1173-2563</issn><issn pub-type="epub">1179-1918</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25258162</article-id><article-id pub-id-type="pmc">4210642</article-id><article-id pub-id-type="publisher-id">233</article-id><article-id pub-id-type="doi">10.1007/s40261-014-0233-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Quality of Life in Patients with Irritable Bowel Syndrome (IBS), Assessed Using the IBS&#x02013;Quality of Life (IBS-QOL) Measure After 4 and 8&#x000a0;Weeks of Treatment with Mebeverine Hydrochloride or Pinaverium Bromide: Results of an International Prospective Observational Cohort Study in Poland, Egypt, Mexico and China</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Xiaohua</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Shengliang</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yali</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Sha</surname><given-names>Weihong</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Xiaofeng</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Elsawah</surname><given-names>Hesham</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Afifi</surname><given-names>Afifi Fahmy</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>El-Khayat</surname><given-names>Hisham Raafat</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Nouh</surname><given-names>Alaa</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Hassan</surname><given-names>Mohamed Fathalla</given-names></name><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Fatah</surname><given-names>Ayman Abdel</given-names></name><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author"><name><surname>Rucker Joerg</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;nchez N&#x000fa;&#x000f1;ez</surname><given-names>Juan Manuel</given-names></name><xref ref-type="aff" rid="Aff13"/></contrib><contrib contrib-type="author"><name><surname>Osthoff Rueda</surname><given-names>Rodolfo</given-names></name><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Jurkowska</surname><given-names>Grazyna</given-names></name><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Walczak</surname><given-names>Michal</given-names></name><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author"><name><surname>Malecka-Panas</surname><given-names>Ewa</given-names></name><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author"><name><surname>Linke</surname><given-names>Krzysztof</given-names></name><xref ref-type="aff" rid="Aff18"/></contrib><contrib contrib-type="author"><name><surname>Hartleb</surname><given-names>Marek</given-names></name><xref ref-type="aff" rid="Aff19"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Janssen-van Solingen</surname><given-names>Gwendolyn</given-names></name><address><email>gwendolyn.janssen@abbott.com</email></address><xref ref-type="aff" rid="Aff20"/></contrib><aff id="Aff1"><label/>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China </aff><aff id="Aff2"><label/>Shanghai Renji Hospital, Shanghai, China </aff><aff id="Aff3"><label/>Nanfang Hospital, Guangzhou, China </aff><aff id="Aff4"><label/>Guangdong General Hospital, Guangzhou, China </aff><aff id="Aff5"><label/>Huadong Hospital, Fudan University, Shanghai, China </aff><aff id="Aff6"><label/>El-Hourya St. Almaza, Cairo, Egypt </aff><aff id="Aff7"><label/>Almoder St. Zgazeg, El Sharkya, Egypt </aff><aff id="Aff8"><label/>El-Nile St., Warrak El-Hader, Imbaba, Giza, Egypt </aff><aff id="Aff9"><label/>45 Doki St., Doki Square, Giza, Egypt </aff><aff id="Aff10"><label/>Safia Zaghloul St., Portsaid, Egypt </aff><aff id="Aff11"><label/>Noor El Islam Private Hospital, Alexandria, Egypt </aff><aff id="Aff12"><label/>Clinical Research Institute, Tlalnepantla, Mexico </aff><aff id="Aff13"><label/>Privada de Constituci&#x000f3;n, Guzman Jalizco, Mexico </aff><aff id="Aff14"><label/>Torre Medica Tampico, Tampico, Mexico </aff><aff id="Aff15"><label/>Praktyka Lekarska ul., Bia&#x00142;ystok, Poland </aff><aff id="Aff16"><label/>NZOZ VITAMED Gastroenterology ul., Bydgoszcz, Poland </aff><aff id="Aff17"><label/>Medical University of &#x00141;&#x000f3;d&#x0017a;, Lodz, Poland </aff><aff id="Aff18"><label/>Gabinet Lekarski Pawe&#x00142; Klincewicz, ul., Pazna&#x00144;, Poland </aff><aff id="Aff19"><label/>Praktyka Lekarska, ul., Katowice, Poland </aff><aff id="Aff20"><label/>Abbott Product Operations AG, Allschwil, EPD Headquarters, Hegenheimermattweg 127, 4123 Allschwil, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>34</volume><issue>11</issue><fpage>783</fpage><lpage>793</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background and Objective</title><p>Irritable Bowel Syndrome (IBS) has a substantial impact on health-related quality of life (HR-QoL) but high-quality data pre- and post-treatment using the IBS&#x02013;Quality of Life (IBS-QOL) measure are limited. The objective of this study was to evaluate the changes from baseline of the IBS-QOL scores, symptom scores and health economic data in IBS patients, after 4 and 8&#x000a0;weeks of treatment with mebeverine hydrochloride or pinaverium bromide.</p></sec><sec><title>Methods</title><p>This was a prospective observational cohort study in patients with IBS, diagnosed using the Rome&#x000a0;III criteria in four countries (Poland, Egypt, Mexico and China).</p></sec><sec><title>Results</title><p>A total of 607 patients were enrolled. At baseline, the IBS-QOL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China and 56.4 overall. Increases in IBS-QOL total score were statistically significant at Weeks&#x000a0;4 and 8 overall and in each country (overall: 11.8 at Week&#x000a0;4, 24.3 at Week&#x000a0;8; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Improvements were shown in all IBS-QOL subscales and scores. Symptoms and health economic outcomes were improved. Furthermore, the favourable safety profile of these treatments was confirmed in this study.</p></sec><sec><title>Conclusions</title><p>This study demonstrated that IBS patients have a substantially reduced HR-QoL and that treatment with mebeverine hydrochloride or pinaverium bromide improved HR-QoL.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d30e460"><title>Key Points</title><p><table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">We performed a prospective, observational cohort study in patients with Irritable Bowel Syndrome (IBS), diagnosed using the Rome&#x000a0;III criteria in four countries (Poland, Egypt, Mexico and China) assessing quality of life pre- and post-treatment (at 4 and 8&#x000a0;weeks) using the IBS-QOL measure.</td></tr><tr><td align="left">Treatment with mebeverine hydrochloride in Poland, Egypt and Mexico, and pinaverium bromide in China confirmed treatment effectiveness in terms of improvement in all IBS-QOL subscales and scores. Results were statistically significant and exceeded the minimal important response (&#x02265;10.2) for the IBS-QOL total score (change from baseline at Week&#x000a0;4). At Week&#x000a0;8, the increase in the IBS-QOL total score was 24.3, greatly exceeding the meaningful clinical response (considered to be an increase of at least 14).</td></tr><tr><td align="left">The favourable safety profile of treatment with either mebeverine hydrochloride or pinaverium bromide was confirmed in this study.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1" sec-type="intro"><title>Introduction</title><p>Irritable Bowel Syndrome (IBS) has a substantial impact on health-related quality of life (HR-QoL) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The impact of IBS on quality of life (QOL) is often underestimated in patients as they do not appear to be disabled in any obvious way and there is no apparent impact on life expectancy [<xref ref-type="bibr" rid="CR3">3</xref>]. QoL in IBS patients has been documented to be even lower than QoL of diabetes mellitus, dialysis-dependent end-stage renal disease or gastroesophageal reflux patients [<xref ref-type="bibr" rid="CR4">4</xref>]. As there are limited data available pre- and post-treatment and specifically with mebeverine hydrochloride and pinaverium bromide [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], this study was initiated to obtain QoL data in different regions of the world, using these treatments within a single study and using the IBS&#x02013;Quality of Life (IBS-QOL) measure [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Mebeverine hydrochloride (Duspatal<sup>&#x000ae;</sup>, Duspatalin<sup>&#x000ae;</sup>, Colofac<sup>&#x000ae;</sup>, Colotal<sup>&#x000ae;</sup>, Mebeverin(e-i-a)<sup>&#x000ae;</sup>, Colospa<sup>&#x000ae;</sup>, Rudakol<sup>&#x000ae;</sup>, Boots IBS relief<sup>&#x000ae;</sup>, Fomac<sup>&#x000ae;</sup>, Mebecon<sup>&#x000ae;</sup>) is a musculotropic antispasmodic with a direct effect on the smooth muscle of the gastrointestinal tract, relieving spasm without affecting normal gut motility. Pinaverium bromide (Dicetel<sup>&#x000ae;</sup>, Eldicet<sup>&#x000ae;</sup>) is an antispasmodic that selectively acts on the gastrointestinal tract, by inhibiting the influx of calcium into intestinal smooth muscle cells. Both antispasmodics are indicated for the treatment of IBS. Mebeverine hydrochloride is a sodium channel antagonist and pinaverium bromide is a gastrointestinal-selective calcium channel antagonist. Both antispasmodics are available in different dosages. In a pharmacokinetic study, the Duspatalin<sup>&#x000ae;</sup> 200&#x000a0;mg twice-daily formulation has been compared with the 135&#x000a0;mg tablet three times daily and has demonstrated optimal relative bioavailability (103&#x000a0;% for single and 97&#x000a0;% for multiple doses) [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>The IBS-QOL measure is a specific tool developed and validated to assess impairment of QoL in IBS [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The IBS-QOL measure consists of 34 IBS-specific items and a 5-point Likert scale (1&#x000a0;=&#x000a0;not at all, 2&#x000a0;=&#x000a0;slightly, 3&#x000a0;=&#x000a0;moderately, 4&#x000a0;=&#x000a0;quite a bit, 5&#x000a0;=&#x000a0;extremely or a great deal). The sum of the items is transformed into a score (potential range 34&#x02013;100; 100&#x000a0;=&#x000a0;maximum QoL). The IBS-QOL measure contains eight IBS-QOL subscales: dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual concerns and relationships. With regards to interpretation of results, apart from reaching statistical significance, a minimal important response (MIR) for the IBS-QOL measure is an increase of 10.2 and meaningful clinical response (MCR) is an increase of at least 14 [<xref ref-type="bibr" rid="CR10">10</xref>].</p></sec><sec id="Sec2" sec-type="methods"><title>Subjects and Methods</title><sec id="Sec3"><title>Study Design</title><p>The study was performed from July 2012 to August 2013 and took place in Poland, China, Egypt and Mexico. IBS patients were diagnosed according to Rome&#x000a0;III diagnostic criteria. Patients were aged &#x02265;18&#x000a0;years, prescribed mebeverine hydrochloride or pinaverium bromide according to the local label, and provided informed consent and written authorisation that their data could be used for analysis. The study of either mebeverine hydrochloride or pinaverium bromide depended on which of the medications were marketed in the countries. The total observational period was 8&#x000a0;weeks, per the US FDA guidance recommendation [<xref ref-type="bibr" rid="CR11">11</xref>]. QoL was assessed after 4 and 8&#x000a0;weeks of treatment as the measure uses a recall period of the previous month (30&#x000a0;days).</p><p>Exclusion criteria were (i) general and specific contraindications to the treatment according to the local label; (ii) being currently treated/having been treated with mebeverine hydrochloride or pinaverium bromide within 4&#x000a0;weeks prior to study entry; (iii) pregnancy/lactation; (iv) other conditions precluding participation (investigator judgment); and (vii) previous enrolment in present study.</p><p>The study was approved by local independent ethics committees (IECs) in China and Mexico and by a central IEC in Poland. There was no requirement for IEC approval in Egypt. The study was registered or approved by regulatory authorities as applicable, and published on ClinicalTrials.gov on 13&#x000a0;July 2012 (NCT01678781).</p><p>Treatments were taken in accordance with both local marketing authorisation and the prescribing information&#x02014;Poland: Duspatalin retard<sup>&#x000ae;</sup> 200&#x000a0;mg twice daily; Egypt: Duspatalin<sup>&#x000ae;</sup> 135&#x000a0;mg three times daily; Mexico: Duspatalin<sup>&#x000ae;</sup> 200&#x000a0;mg twice daily; and China: Dicetel<sup>&#x000ae;</sup> 50&#x000a0;mg three times daily. The Duspatalin retard<sup>&#x000ae;</sup> 200&#x000a0;mg capsule formulation is a prolonged-release formulation, which explains why a twice-daily regimen is sufficient; whereas the 135&#x000a0;mg tablet is an immediate-release formulation, requiring a three-times-daily treatment regimen.</p><p>IBS-QOL questionnaires were completed electronically by the patient at each visit using an electronic patient-reported outcome (ePRO) instrument.</p><p>Other symptom assessments were entered directly into the electronic case report form (eCRF).</p></sec><sec id="Sec4"><title>Statistical Analysis</title><p>There were two patient samples defined for the study analyses: a safety analysis set (SAS), consisting of all patients who have received at least one dose of study medication, and a full analysis set (FAS), consisting of all patients in the SAS who had any post-baseline QoL data. Demographic and safety analyses were carried out using the SAS and efficacy analysis was carried out on the FAS.</p><p>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> details the primary and secondary objectives of effectiveness, assessed after 4 and 8&#x000a0;weeks of treatment.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Primary and secondary objectives</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Primary objective</td></tr><tr><td align="left">&#x02003;Change from baseline in IBS-QOL total score</td></tr><tr><td align="left">Secondary objectives</td></tr><tr><td align="left">&#x02003;Changes from baseline in the 8 IBS-QOL subscales (scores)</td></tr><tr><td align="left">&#x02003;Change from baseline in IBS-QOL total and subscale scores within patient subgroups (IBS-C, IBS-D, IBS-M, sex and age)</td></tr><tr><td align="left">&#x02003;Change from baseline in IBS symptom score:</td></tr><tr><td align="left">&#x02003;&#x02003;abdominal pain (none/mild/moderate/severe/incapacitating)</td></tr><tr><td align="left">&#x02003;&#x02003;stool frequency (mean number per day during last week prior to visit)</td></tr><tr><td align="left">&#x02003;&#x02003;straining (present/absent)</td></tr><tr><td align="left">&#x02003;&#x02003;urgency (present/absent)</td></tr><tr><td align="left">&#x02003;&#x02003;feeling of incomplete defecation (present/absent)</td></tr><tr><td align="left">&#x02003;&#x02003;passage of mucus (present/absent)</td></tr><tr><td align="left">&#x02003;&#x02003;bloating or feeling of abdominal distension (present/absent)</td></tr><tr><td align="left">&#x02003;Change from baseline in gastrointestinal symptoms (number of occurrences during last week prior to visit):</td></tr><tr><td align="left">&#x02003;&#x02003;heartburn</td></tr><tr><td align="left">&#x02003;&#x02003;early satiety</td></tr><tr><td align="left">&#x02003;&#x02003;postprandial fullness</td></tr><tr><td align="left">&#x02003;&#x02003;nausea</td></tr><tr><td align="left">&#x02003;&#x02003;vomiting</td></tr><tr><td align="left">&#x02003;Health economic data<sup>a</sup>
</td></tr><tr><td align="left">&#x02003;Evaluate the safety of mebeverine hydrochloride/pinaverium bromide by country and overall</td></tr></tbody></table><table-wrap-foot><p>
<italic>IBS</italic> irritable bowel syndrome, <italic>IBS-C</italic> IBS with constipation, <italic>IBS-D</italic> IBS with diarrhoea, <italic>IBS-M</italic> IBS-mixed (constipation and diarrhoea), <italic>IBS-QOL</italic> IBS&#x02013;Quality of Life</p><p>
<sup>a</sup> After 8&#x000a0;weeks of treatment only</p></table-wrap-foot></table-wrap></p><p>The required per-country sample size was 119&#x000a0;patients, securing a comparison-wise statistical power of 95&#x000a0;%. This sample size was based on the following assumptions: a mean baseline IBS-QOL total score of 60; an MIR from baseline &#x0003e;10; and a standard deviation of the change scores of 30 [<xref ref-type="bibr" rid="CR10">10</xref>]. To allow for dropouts, and given that this number was an approximation, a per-country sample size of 133 patients resulted.</p><p>Statistical analysis of changes from baseline in total scores and subscores was performed using the Wilcoxon signed&#x02013;rank test. A <italic>p</italic>&#x000a0;value&#x000a0;&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec5" sec-type="results"><title>Results</title><sec id="Sec6"><title>Disposition and Demographics</title><p>All patients (<italic>n</italic>&#x000a0;=&#x000a0;607) received at least one dose of study drug and were included in the SAS. A total of 596/607 patients (98.2&#x000a0;%) had post-baseline QoL data&#x02014;the FAS. Per country, the FAS consisted of: Poland&#x02014;133&#x000a0;patients, 99.3&#x000a0;%; Egypt&#x02014;208&#x000a0;patients, 99.5&#x000a0;%; Mexico&#x02014;120 patients, 99.2&#x000a0;%; and China&#x02014;135 patients, 94.4&#x000a0;%.</p><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows patient disposition and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> summarises the demographic data.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Patient disposition (all patients)</p></caption><graphic xlink:href="40261_2014_233_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Summary of demographic data by country and overall (safety analysis set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristic</th><th align="left">Poland</th><th align="left">Egypt</th><th align="left">Mexico</th><th align="left">China</th><th align="left">Overall</th></tr><tr><th align="left">(<italic>n</italic>&#x000a0;=&#x000a0;134)</th><th align="left">(<italic>n</italic>&#x000a0;=&#x000a0;209)</th><th align="left">(<italic>n</italic>&#x000a0;=&#x000a0;121)</th><th align="left">(<italic>n</italic>&#x000a0;=&#x000a0;143)</th><th align="left">(<italic>n</italic>&#x000a0;=&#x000a0;607)</th></tr></thead><tbody><tr><td align="left">Sex [<italic>n</italic> (%)]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Male</td><td align="left">47 (35.1)</td><td align="left">99 (47.4)</td><td align="left">25 (20.7)</td><td align="left">74 (51.7)</td><td align="left">245 (40.4)</td></tr><tr><td align="left">&#x02003;Female</td><td align="left">87 (64.9)</td><td align="left">110 (52.6)</td><td align="left">96 (79.3)</td><td align="left">69 (48.3)</td><td align="left">362 (59.6)</td></tr><tr><td align="left">Race [<italic>n</italic> (%)]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Asian</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">143</td><td align="left">143 (23.6)</td></tr><tr><td align="left">&#x02003;Black</td><td align="left">0</td><td align="left">3 (1.4)</td><td align="left">0</td><td align="left">(100.0)</td><td align="left">3 (0.5)</td></tr><tr><td align="left">&#x02003;White</td><td align="left">134 (100.0)</td><td align="left">0</td><td align="left">15 (12.5)</td><td align="left">0</td><td align="left">149 (24.6)</td></tr><tr><td align="left">&#x02003;Other</td><td align="left">0</td><td align="left">206 (98.6)</td><td align="left">105 (87.5)</td><td align="left">0</td><td align="left">311 (51.3)</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td></tr><tr><td align="left">Age (<italic>n</italic>)</td><td align="left">134</td><td align="left">209</td><td align="left">120</td><td align="left">143</td><td align="left">606</td></tr><tr><td align="left">&#x02003;Mean (SD) [years]</td><td align="left">43.8 (14.30)</td><td align="left">37.2 (10.76)</td><td align="left">44.4 (15.36)</td><td align="left">43.6 (13.94)</td><td align="left">41.6 (13.68)</td></tr><tr><td align="left">&#x02003;Minimum, maximum (years)</td><td align="left">20, 74</td><td align="left">19, 75</td><td align="left">19, 78</td><td align="left">20, 80</td><td align="left">19, 80</td></tr><tr><td align="left">Age group [<italic>n</italic> (%)]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;18&#x02013;30&#x000a0;years</td><td align="left">26 (19.4)</td><td align="left">69 (33.0)</td><td align="left">26 (21.7)</td><td align="left">27 (18.9)</td><td align="left">148 (24.4)</td></tr><tr><td align="left">&#x02003;31&#x02013;40&#x000a0;years</td><td align="left">36 (26.9)</td><td align="left">58 (27.8)</td><td align="left">30 (25.0)</td><td align="left">42 (29.4)</td><td align="left">166 (27.4)</td></tr><tr><td align="left">&#x02003;41&#x02013;65&#x000a0;years</td><td align="left">63 (47.0)</td><td align="left">81 (38.8)</td><td align="left">49 (40.8)</td><td align="left">66 (46.2)</td><td align="left">259 (42.7)</td></tr><tr><td align="left">&#x02003;&#x0003e;65&#x000a0;years</td><td align="left">9 (6.7)</td><td align="left">1 (0.5)</td><td align="left">15 (12.5)</td><td align="left">8 (5.6)</td><td align="left">33 (5.4)</td></tr><tr><td align="left">&#x02003;Out of range/missing age</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td></tr><tr><td align="left">Subgroup of IBS [<italic>n</italic>&#x000a0;(%)]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;IBS-C</td><td align="left">21 (15.7)</td><td align="left">55 (26.3)</td><td align="left">77 (64.2)</td><td align="left">20 (14.0)</td><td align="left">173 (28.5)</td></tr><tr><td align="left">&#x02003;IBS-D</td><td align="left">70 (52.2)</td><td align="left">62 (29.7)</td><td align="left">23 (19.2)</td><td align="left">97 (67.8)</td><td align="left">252 (41.6)</td></tr><tr><td align="left">&#x02003;IBS-M</td><td align="left">43 (32.1)</td><td align="left">92 (44.0)</td><td align="left">20 (16.7)</td><td align="left">26 (18.2)</td><td align="left">181 (29.9)</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td></tr></tbody></table><table-wrap-foot><p>Percentages are based on the number of patients with non-missing data in the respective group</p><p>
<italic>IBS</italic> irritable bowel syndrome, <italic>IBS-C</italic> IBS with constipation, <italic>IBS-D</italic> IBS with diarrhoea, <italic>IBS-M</italic> IBS&#x02014;mixed (constipation and diarrhoea), <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap></p><p>Patients in Poland, Egypt and Mexico received treatment with mebeverine hydrochloride and patients in China received treatment with pinaverium bromide. Overall, 464/607 patients (76.4&#x000a0;%) received mebeverine and 143/607 patients (23.6&#x000a0;%) received pinaverium.</p><p>A total of 259 (42.7&#x000a0;%) patients reported taking concomitant medication at the start of or during the study. Concomitant medication was indicated for both IBS and other conditions.</p><p>With regards to IBS subgroups, the IBS with constipation (IBS-C) subgroup was far more prevalent in Mexico and the IBS with diarrhoea (IBS-D) subgroup was far more prevalent in China.</p></sec><sec id="Sec7"><title>Primary Objective</title><sec id="Sec8"><title>Change from Baseline in Irritable Bowel Syndrome (IBS)&#x02013;Quality of Life (IBS-QOL) Total Score</title><p>Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> provides an overview of the mean IBS-QOL total score at baseline, after 4 and 8 weeks, as well as the statistical analyses of the primary objective of the change from baseline in IBS QOL total score at Weeks 4 and 8 (FAS).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Statistical analyses of the primary objective of the change from baseline in the Irritable Bowel Syndrome&#x02013;Quality of Life (IBS-QOL) total score at Weeks 4 and 8</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Visit</th><th align="left" colspan="5">IBS-QOL total score<sup>a</sup>
</th></tr><tr><th align="left">Poland</th><th align="left">Egypt</th><th align="left">Mexico</th><th align="left">China</th><th align="left">Overall</th></tr></thead><tbody><tr><td align="left">Week 0 (baseline)</td><td align="left">52.0 (18.32)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;133)</td><td align="left">48.9 (18.58)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;206)</td><td align="left">51.9 (18.62)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;120)</td><td align="left">76.4 (14.18)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;134)</td><td align="left">56.4 (20.68)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;593)</td></tr><tr><td align="left">Week 4</td><td align="left">65.4 (17.28)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;132)</td><td align="left">63.7 (15.18)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;208)</td><td align="left">60.2 (16.56)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;111)</td><td align="left">83.7 (12.03)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;129)</td><td align="left">67.8 (17.57)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td></tr><tr><td align="left">Week 8</td><td align="left">75.1 (18.09)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;132)</td><td align="left">78.0 (12.36)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;205)</td><td align="left">83.8 (13.65)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;119)</td><td align="left">87.1 (11.25)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;129)</td><td align="left">80.5 (14.58)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td></tr><tr><td align="left">Change from baseline to Week&#x000a0;4</td><td align="left">13.4 (15.94)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;132)</td><td align="left">14.9 (18.70)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;206)</td><td align="left">8.9 (23.45)**<break/>(<italic>n</italic>&#x000a0;=&#x000a0;111)</td><td align="left">7.7 (11.03)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;128)</td><td align="left">11.8 (17.98)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;577)</td></tr><tr><td align="left">Change from baseline to Week&#x000a0;8</td><td align="left">23.3 (20.44)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;132)</td><td align="left">29.4 (19.18)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;203)</td><td align="left">31.8 (20.89)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;119)</td><td align="left">10.4 (11.98)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;130)</td><td align="left">24.3 (20.13)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;584)</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean (standard deviation)</p><p>
<italic>IBS-QOL</italic> Irritable Bowel Syndrome-Quality of Life, <italic>QoL</italic> quality of life, <sup>*</sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <sup>**</sup>
<italic>p</italic>&#x000a0;=&#x000a0;0.001</p><p>
<sup>a</sup>Scale: 100&#x000a0;=&#x000a0;best possible QOL, 0&#x000a0;=&#x000a0;worst possible QoL</p></table-wrap-foot></table-wrap></p><p>At baseline, the IBS-QOL mean total scores were similar and ranged from 48.9 to 52.0 but China had a significantly higher score of 76.4. Statistical analysis of the primary objective of IBS-QOL total score showed a statistically significant increase from baseline at Week&#x000a0;4 and&#x000a0;8, in each country and overall. The mean increase from baseline was greater at Week&#x000a0;8 (overall 24.3; range by country 10.4&#x02013;31.8) than Week&#x000a0;4 (overall 11.8; range by country 7.7&#x02013;14.9). For each country the increase at Week&#x000a0;8 was greater than at Week&#x000a0;4.</p></sec></sec><sec id="Sec9"><title>Secondary Objectives</title><sec id="Sec10"><title>Change from Baseline in IBS-QOL Subscales</title><p>Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> displays and Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> summarises the results regarding the IBS subscales (per country and overall, respectively).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Change from baseline, in Irritable Bowel Syndrome&#x02013;Quality of Life (IBS-QOL) subscale scores at Weeks 4 and 8 in Poland (<bold>a</bold>), China (<bold>b</bold>), Egypt (<bold>c</bold>) and Mexico (<bold>d</bold>)</p></caption><graphic xlink:href="40261_2014_233_Fig2a_HTML" id="MO2"/><graphic xlink:href="40261_2014_233_Fig2b_HTML" id="MO3"/></fig><table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Statistical analyses of the secondary endpoint of the change from baseline, overall, in Irritable Bowel Syndrome&#x02013;Quality of Life subscale scores at Weeks 4 and 8</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Visit</th><th align="left" colspan="8">IBS-QOL subscale score<sup>a</sup>
</th></tr><tr><th align="left">Dysphoria</th><th align="left">Interference with activity</th><th align="left">Body image</th><th align="left">Health worry</th><th align="left">Food avoidance</th><th align="left">Social reaction</th><th align="left">Sexual</th><th align="left">Relationships</th></tr></thead><tbody><tr><td align="left">Week 0 (baseline)</td><td align="left">53.0 (23.56)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;595)</td><td align="left">54.4 (21.93)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;595)</td><td align="left">58.8 (24.87)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;596)</td><td align="left">51.8 (24.97)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;596)</td><td align="left">43.7 (25.55)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;596)</td><td align="left">63.9 (24.92)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;596)</td><td align="left">71.0 (27.97)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;594)</td><td align="left">63.8 (25.14)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;596)</td></tr><tr><td align="left">Week 4</td><td align="left">67.0 (19.57)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">64.0 (20.17)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">70.4 (19.78)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">66.6 (22.3)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">55.4 (24.31)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">73.8 (19.32)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">79.5 (21.13)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">73.5 (19.41)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td></tr><tr><td align="left">Week 8</td><td align="left">80.8 (16.39)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">78.3 (16.51)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">81.3 (16.89)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">80.5 (17.24)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">69.0 (21.13)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">84.7 (16.32)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">88.5 (16.92)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;586)</td><td align="left">84.4 (16.25)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td></tr><tr><td align="left">Change from baseline to Week&#x000a0;4</td><td align="left">14.4 (20.66)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;579)</td><td align="left">10.0 (21.14)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;579)</td><td align="left">11.7 (20.68)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">15.1 (22.35)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">12.1 (23.35)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">10.1 (21.10)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td><td align="left">8.4 (24.56)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;578)</td><td align="left">10.0 (22.43)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;580)</td></tr><tr><td align="left">Change from baseline to Week&#x000a0;8</td><td align="left">27.9 (23.79)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;586)</td><td align="left">24.0 (21.72)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;586)</td><td align="left">22.6 (23.39)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">28.9 (25.03)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">25.4 (26.16)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">21.0 (22.59)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td><td align="left">17.4 (26.57)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;585)</td><td align="left">20.7 (23.82)*<break/>(<italic>n</italic>&#x000a0;=&#x000a0;587)</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean (standard deviation)</p><p>
<italic>IBS-QOL</italic> Irritable Bowel Syndrome&#x02013;Quality Of Life, <italic>QoL</italic> quality of life, <sup>*</sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001</p><p>
<sup>a</sup>Scale: 100&#x000a0;=&#x000a0;best possible QoL, 0&#x000a0;=&#x000a0;worst possible QoL</p></table-wrap-foot></table-wrap></p><p>There was a statistically significant increase from baseline in IBS-QOL for all subscales at Week&#x000a0;4 and&#x000a0;8, overall. Also, for each country, there was a statistically significant increase at Week&#x000a0;4 and&#x000a0;8, with the exception of interference with activity and social reaction in Mexico at Week&#x000a0;4 only. At Week&#x000a0;4, the increases for subscales for health worry, dysphoria, food avoidance and body image exceeded the MIR, whereas for social reaction and interference with activity and relationships, the increases were just below the MIR at 10.0 or 10.1. For sexual concerns, the increase was lower at 8.4. For each subscale, overall and in each country, the mean increase at Week&#x000a0;8 was greater than at Week&#x000a0;4.</p><p>Patients in Poland, Egypt and Mexico had similar mean baseline scores for the subscales and responses in Poland and Egypt at Week&#x000a0;4 were comparable, whereas in Mexico all mean responses, with the exception of &#x02018;body image&#x02019; and &#x02018;sexual&#x02019;, were lower. By Week&#x000a0;8, the mean response for patients in Poland, Egypt and Mexico was similar. In China, the patients had higher baseline subscale scores and response at Week&#x000a0;4 and Week&#x000a0;8 was less than in the other countries, which was most apparent for &#x02018;body image&#x02019; and &#x02018;relationships&#x02019;.</p></sec></sec><sec id="Sec11"><title>Analysis of IBS Subgroups</title><p>There was a mean increase from baseline in IBS-QOL total and subscales for all IBS subgroups at Weeks 4 and&#x000a0;8. For each total score and subscale, overall and in each country, the increase at Week&#x000a0;8 was greater than at Week&#x000a0;4. The response in patients with IBS-D at both Week&#x000a0;4 and&#x000a0;8 was lower than for patients with IBS-C and irritable bowel syndrome&#x02014;mixed (constipation and diarrhoea) (IBS-M), suggesting that patients with IBS-D respond less well to treatment than those with IBS-C and IBS-M. Lower responses were seen for the IBS subgroups in Mexico at Week&#x000a0;4 (as for all IBS patients combined), with the response for IBS-C patients and particularly IBS-D patients being lower there than those patient subgroups in Poland and Egypt. In China, the IBS-QOL total score for each IBS subgroup showed a higher baseline and response was lower at Weeks 4 and 8. Evaluation of the subscales showed responses for IBS-D patients being consistently lower than for IBS-C and IBS-M patients.</p></sec><sec id="Sec12"><title>Analysis by Sex and Age</title><p>There was no notable difference according to sex regarding the increase in IBS-QOL total scores at Week&#x000a0;4 and 8. Females had slightly lower mean baseline IBS-QOL total scores and showed a greater mean increase from baseline than males at Week&#x000a0;8 in all countries with the exception of Egypt. There was no apparent difference in response with increasing age.</p></sec><sec id="Sec13"><title>IBS and Gastrointestinal Symptom Scores</title><p>Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> summarises the IBS symptom scores for abdominal pain and discomfort.<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Irritable bowel syndrome symptom scores for abdominal pain/discomfort at baseline and after 4&#x000a0;and 8&#x000a0;weeks of treatment with mebeverine hydrochloride or pinaverium bromide by country and overall</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Visit</th><th align="left" colspan="5">Mean abdominal pain/discomfort: IBS symptom scores<sup>a</sup>
</th></tr><tr><th align="left">Poland (<italic>n</italic>&#x000a0;=&#x000a0;133)</th><th align="left">Egypt (<italic>n</italic>&#x000a0;=&#x000a0;208)</th><th align="left">Mexico (<italic>n</italic>&#x000a0;=&#x000a0;120)</th><th align="left">China (<italic>n</italic>&#x000a0;=&#x000a0;135)</th><th align="left">Overall (<italic>n</italic>&#x000a0;=&#x000a0;596)</th></tr></thead><tbody><tr><td align="left">Week 0 (baseline)</td><td align="left">2.0 (0.63)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;133)</td><td align="left">2.0 (0.66)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;208)</td><td align="left">2.3 (0.83)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;120)</td><td align="left">1.5 (0.68)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;135)</td><td align="left">2.0 (0.74)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;596)</td></tr><tr><td align="left">Change from baseline to Week&#x000a0;4</td><td align="left">&#x02212;0.9 (0.73)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;133)</td><td align="left">&#x02212;0.9 (0.77)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;208)</td><td align="left">&#x02212;1.4 (1.02)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;111)</td><td align="left">&#x02212;0.7 (0.81)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;130)</td><td align="left">&#x02212;0.9 (0.86)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;582)</td></tr><tr><td align="left">Change from baseline to Week&#x000a0;8</td><td align="left">&#x02212;1.3 (0.80)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;132)</td><td align="left">&#x02212;1.4 (0.78)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;208)</td><td align="left">&#x02212;1.9 (1.08)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;120)</td><td align="left">&#x02212;1.0 (0.87)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;131)</td><td align="left">&#x02212;1.3 (0.92)<break/>(<italic>n</italic>&#x000a0;=&#x000a0;591)</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean (standard deviation)</p><p>
<italic>IBS</italic> irritable bowel syndrome</p><p>
<sup>a</sup>Scale: 0&#x000a0;=&#x000a0;none, 1&#x000a0;=&#x000a0;mild, 2&#x000a0;=&#x000a0;moderate, 3&#x000a0;=&#x000a0;severe, 4&#x000a0;=&#x000a0;incapacitating</p></table-wrap-foot></table-wrap></p><p>There was a mean decrease in abdominal discomfort/pain at Week&#x000a0;4 and a further decrease at Week&#x000a0;8 in all countries (overall: &#x02212;0.9 at Week&#x000a0;4 compared with &#x02212;1.3 at Week&#x000a0;8).</p><p>Analysis of IBS-C and IBS-D subgroups showed improvements for both stool frequency and stool form. Overall for IBS-C, there was a mean increase from baseline of 0.4 per day for stool frequency at Weeks 4 and 8 and a mean increase in stool form of 0.6 (Week&#x000a0;4) and 0.7 (Week&#x000a0;8). Overall for IBS-D, there was a mean decrease at Weeks&#x000a0;4 and&#x000a0;8 (&#x02212;0.9 and &#x02212;1.2 per day, respectively) for stool frequency and for stool form of &#x02212;1.4 (Week&#x000a0;4) and &#x02212;1.6 (Week&#x000a0;8).</p><p>Overall, patients showed consistent improvement across the IBS symptoms of straining, urgency, feeling of incomplete defecation, passage of mucus and bloating/feeling of abdominal distension. These symptoms were present in 41.6&#x02013;79.9&#x000a0;% of patients at baseline; they showed an improvement in 26.1&#x02013;36.6&#x000a0;% of patients at Week&#x000a0;4 and in 37.2&#x02013;47.4&#x000a0;% of patients at Week&#x000a0;8. For the IBS subgroups, 87.2&#x000a0;% of IBS-C patients experienced bloating or a feeling of abdominal distension at baseline and showed a notable improvement from Week&#x000a0;4 to Week&#x000a0;8 (26.3 to 55.9&#x000a0;% of patients) and for IBS-D patients, 75.2&#x000a0;% of patients had a feeling of urgency at baseline, which showed the most improvement compared to other IBS symptoms at both Week&#x000a0;4 and Week&#x000a0;8 (47.7 and 59.3&#x000a0;% of patients, respectively). Bloating/abdominal distension is a symptom that is typically reported in the Asian population, and described in Asian consensus guidelines as being one of the most predominant symptoms of IBS. However, within the Rome&#x000a0;III diagnostic criteria, there is no mention of bloating; therefore, it is of interest to have data on improvement of symptoms of bloating/abdominal distension with treatment on top of data regarding the QoL.</p><p>There was a mean decrease from baseline for all gastrointestinal symptoms (number of occurrences during the last week prior to visit): heartburn (&#x02212;0.5), early satiety (&#x02212;0.7), postprandial fullness (&#x02212;0.8), nausea (&#x02212;0.5) and vomiting (&#x02212;0.2) at Week&#x000a0;4. For heartburn, early satiety and postprandial fullness, there was a greater decrease from baseline at Week&#x000a0;8 (means of &#x02212;0.7, &#x02212;1.0 and &#x02212;1.2, respectively), whereas for nausea and vomiting there was no further change at Week&#x000a0;8 versus Week&#x000a0;4.</p></sec><sec id="Sec14"><title>Health Economic Data</title><p>The health economic data showed that no patients spent any days in hospital due to their IBS in the 8-week treatment period, compared to a mean of 0.2&#x000a0;days (patients in Egypt, Mexico and China only) in the 8-week period prior to baseline. For the patients currently employed, a mean of 0.1&#x000a0;days (patients in Poland, Egypt and China only) was missed from work during the 8&#x000a0;weeks of treatment due to IBS, compared with a mean of 1.2&#x000a0;days (patients in all countries) in the 8-week period prior to baseline.</p></sec><sec id="Sec15"><title>Safety</title><p>Treatment was well-tolerated. The incidence of adverse events (AEs) was low (3.3&#x000a0;% of patients), the most frequently reported being headache (three patients) and pharyngitis and upper respiratory tract infection (in two patients each). Twenty patients reported a total of 21 AEs. Two AEs considered possibly drug-related were abdominal distension (moderate severity) and somnolence (mild severity), both of which were non-serious and ongoing at the end of the study period; both occurred with mebeverine. The other 19 AEs were considered unrelated to study treatment. A serious AE of mild haemorrhoids (requiring hospitalization for surgery) was not considered drug-related by the investigator (in China). A pregnancy was reported after the start of the study, which is currently ongoing (in Egypt).</p></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p>The IBS-QOL [<xref ref-type="bibr" rid="CR7">7</xref>] questionnaire was developed by Patrick and Drossman [<xref ref-type="bibr" rid="CR7">7</xref>] in the 1990s and further validation has confirmed the responsiveness of the scale [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. A systematic review has appraised the IBS-QOL measure as the best of five IBS-specific QoL scores available and assessed to establish changes in HR-QoL [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>This study (596&#x000a0;IBS patients, 59.6&#x000a0;% females, assessed using the Rome&#x000a0;III criteria) shows a mean, overall IBS-QOL total score at baseline of 56.4, indicative of moderate/severe disease and is consistent with an international survey of patients with IBS published by Drossman et al. in 2009, where patients also met Rome&#x000a0;III criteria for IBS in 90.8&#x000a0;% of the cases (1,966&#x000a0;patients; 83&#x000a0;% female, 91&#x000a0;% Caucasian, 78&#x000a0;% USA/Canada) [<xref ref-type="bibr" rid="CR2">2</xref>] and where the overall mean at baseline was 51.1.</p><p>In this study, the impairment at baseline was similar in Egypt, Mexico and Poland (mean IBS-QOL total scores of 48.9&#x02013;52.0), but lower in China at 76.4 (indicative of mild/moderate disease). Of note, there are no general practitioners in China and patients consult specialist care immediately, which potentially explains severity of disease being less in China at baseline; thereby leaving a smaller relative room for improvement. Previous studies have shown different mean baseline IBS-QOL total scores, using different diagnostic criteria, a different male/female ratio, different IBS subtyping distribution and different geographical locations: 70.3 (30&#x000a0;Japanese patients, percentage females/males not stated, Rome&#x000a0;II diagnosis) [<xref ref-type="bibr" rid="CR3">3</xref>]; 66.3 (1,555&#x000a0;patients in Canada, 85.1&#x000a0;% females, physician diagnosed) [<xref ref-type="bibr" rid="CR13">13</xref>]; and 64.3 (value adjusted for age, education, race, marital status) (317&#x000a0;patients in Canada, 100&#x000a0;% females, Rome&#x000a0;I diagnosis) [<xref ref-type="bibr" rid="CR10">10</xref>]. These differences may reflect known cross-cultural differences across countries (e.g. race, food or lifestyle) and variation in diagnosis and sex of patients. In this study, all patients were diagnosed according to the Rome&#x000a0;III criteria, so the diagnosis of IBS (Rome&#x000a0;III) is not a contributory factor to the higher baseline seen in China.</p><p>For the IBS-QOL, Drossman et al. [<xref ref-type="bibr" rid="CR10">10</xref>] reported an MIR to be an increase of 10.2 and an MCR to be an increase&#x000a0;&#x02265;14. In this study, the overall change from baseline in IBS-QOL total score at Week&#x000a0;4 of 11.8 achieved the MIR and by Week&#x000a0;8 the improvement of 24.3 greatly exceeded the MCR.</p><p>In this study, the greatest impairment at baseline (determined as scores&#x000a0;&#x0003c;55) was observed for the subscale of food avoidance (43.7), health worry (51.8), dysphoria (53.0) and interference with activity (54.4). These findings were similar to the previously mentioned international survey results [<xref ref-type="bibr" rid="CR2">2</xref>], where the greatest impairments of similar magnitude were shown for food avoidance, dysphoria and interference with activity, but not health worry. In Japanese patients [<xref ref-type="bibr" rid="CR3">3</xref>], food avoidance, dysphoria and interference with activity also showed the greatest impairment. Studies in Canada showed the greatest baseline impairment in food avoidance, health worry and body image [<xref ref-type="bibr" rid="CR13">13</xref>], and for food avoidance, interference with activities and dysphoria [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>The greatest improvements in IBS-QOL in this study, after 8&#x000a0;weeks of treatment, were observed for the subscales of food avoidance, health worry, dysphoria and interference with activity; with these subscales having the lowest pre-treatment scores, they have a greater potential for improvement. Similar findings to this study have been previously reported [<xref ref-type="bibr" rid="CR2">2</xref>], with the exception of social reaction also having a greater improvement and replacing food avoidance. The remaining subscales of body image, social reaction, sexual concerns and relationships in this study all showed clinically meaningful responses at 8&#x000a0;weeks (range 17.4&#x02013;28.9).</p><p>Randomised placebo-controlled trials conducted in patients with IBS tend to be characterised by a relatively high placebo response. Considering the fact that a placebo effect generally tends to occur early in treatment and is less likely to persist, and the IBS-QOL scores increasing up to Week&#x000a0;8, this does not appear to have significantly impacted the outcome of the study; albeit a certain degree of placebo response cannot be completely excluded. Patel et al. [<xref ref-type="bibr" rid="CR14">14</xref>] have demonstrated that fulfilment of the Rome criteria for study entry and an increased number of office visits are significantly associated with a lower placebo response rate. By requiring patients to fulfil the Rome&#x000a0;III criteria, and by having three visits within the 8-week treatment period, a proactive effort was made to contribute to a lower placebo response rate.</p><p>Abdominal pain is one of the main symptoms associated with IBS and a responder has been defined in several studies in IBS patients [<xref ref-type="bibr" rid="CR15">15</xref>] as demonstrating a 50&#x000a0;% decrease in symptom severity. For the IBS symptoms of abdominal pain and discomfort in this study, a mean decrease of &#x0003e;50&#x000a0;% in symptom severity was seen in all countries, and overall, at Week&#x000a0;8.</p><p>This study provides further relevant information on the IBS-QOL measure as a means to determine adequate treatment response. For the clinician, the study attests to the value of the IBS-QOL as a &#x02018;barometer&#x02019; of the patient&#x02019;s clinical course, more than any biological measure. It provides information on the patient&#x02019;s perception of ill health, and how it is modified for better or worse in response to treatment, and can therefore be used as a yardstick of treatment progress, including when a particular intervention would be considered optimal.</p><p>The limitations of this study are in regard to both the study being observational in design and also to how the findings can be related to other populations. An observational study represents a &#x02018;less perfect&#x02019; experiment than an efficacy trial and there can be issues relating to data quality and completeness, as well as the non-randomised design. The aim of this study, however, was to provide high-quality data by gathering it electronically, and statistical analysis showed significant increases from baseline in IBS-QOL total score at Weeks&#x000a0;4 and 8 for all countries and overall, which could be quantified in terms of a high MCR at Week&#x000a0;8. The findings, however, may not be applicable to men or women with milder or more severe disease, or with other functional gastrointestinal symptoms. The study does provide new information regarding the impact of IBS on HR-QoL and the magnitude of improvement in response to treatment with mebeverine hydrochloride or pinaverium bromide, showing the effectiveness of these treatments in a real-life setting. Many patients in this observational study received treatment for IBS and then in addition received mebeverine hydrochloride or pinaverium bromide, reflective of the real-life setting (where often a combination of medications is given to address the symptoms of the individual patient and IBS subtype) and showing the added value of additional treatment.</p></sec><sec id="Sec17" sec-type="conclusions"><title>Conclusion</title><p>Treatment of patients with IBS with mebeverine hydrochloride in Poland, Egypt and Mexico and pinaverium bromide in China confirmed the effectiveness of the study medication in terms of the improvement in IBS-QOL total scores and subscales. Results were statistically significant and exceeded the MIR (&#x02265;10.2) for the IBS-QOL measure, from baseline, with the changes being greater at Week&#x000a0;8 than Week&#x000a0;4. At Week&#x000a0;8, the increase in the IBS-QOL total score was 24.3, greatly exceeding the MCR (considered to be an increase of at least 14) [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>An improvement in IBS and gastrointestinal symptoms was also shown for the patients overall and for each subgroup (IBS-C, IBS-D and IBS-M). There was also an improvement in the health economic data for the patients, with a reduction during the treatment period in both the number of days spent in hospital and the number of days missed from work. Furthermore, the favourable safety profile of these treatments was confirmed in this study.</p></sec></body><back><fn-group><fn><p>ClinicalTrials.gov identifier: NCT01678781.</p></fn></fn-group><ack><p>We acknowledge Janet Ward, Chiltern International, Slough, UK for medical writing assistance and contributing to clinical study report preparation.</p><p>Investigators that have also contributed to the recruitment of patients: Duowu Zhou (Shanghai, China), Huahong Wang (Beijing, China), Tomasz Arlukowic (Olsztyn, Poland), Jacek Romatowski (Bialystok, Poland), Marek Karczewski (Bydgoszcz, Poland).</p><sec id="d30e2371"><title>Funding</title><p>The research was sponsored by Abbott Products Operations, AG, Allschwil, Switzerland.</p></sec><sec id="d30e2376"><title>Conflict of interest</title><p>Dr. Afifi has lectured for AstraZeneca and Sanofi Aventis. Dr. El-Khayat has provided lectures and has been involved in clinical research for: BMS, MSD, AstraZeneca, Abbott and Gilead. Gwendolyn Janssen-van Solingen is an employee of Abbott Products Operations AG in the position of Global Medical Director Gastroenterology portfolio.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Whitehead</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Further validation of the IBS-QOL: a disease&#x02013;specific, quality&#x02013;of&#x02013;life questionnaire</article-title><source>Am J Gastroenterol</source><year>2000</year><volume>95</volume><issue>4</issue><fpage>999</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2000.01941.x</pub-id><pub-id pub-id-type="pmid">10763950</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Morris</surname><given-names>CB</given-names></name><name><surname>Schneck</surname><given-names>S</given-names></name><etal/></person-group><article-title>International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit</article-title><source>J Clin Gastroenterol</source><year>2009</year><volume>43</volume><issue>6</issue><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1097/MCG.0b013e318189a7f9</pub-id><pub-id pub-id-type="pmid">19384249</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawanawa</surname><given-names>M</given-names></name><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Shonozaki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Translation and validation of a Japanese version of the irritable bowel syndrome quality of life measure (IBS-QOL&#x02013;J)</article-title><source>BioPsychoSoc Med</source><year>2007</year><volume>1</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1751-0759-1-6</pub-id><pub-id pub-id-type="pmid">17371576</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralnek</surname><given-names>IM</given-names></name><name><surname>Hays</surname><given-names>RD</given-names></name><name><surname>Kilbourne</surname><given-names>A</given-names></name><etal/></person-group><article-title>The impact of irritable bowel syndrome on health-related quality of life</article-title><source>Gastroenterology</source><year>2000</year><volume>119</volume><fpage>654</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1053/gast.2000.16484</pub-id><pub-id pub-id-type="pmid">10982758</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">M&#x000f6;nnikes H, Hecker H, Heymann&#x02013;M&#x000f6;nnikes I. Predictive factors for therapeutic success in irritable bowel syndrome (IBS) in primary care (PrC) 2001. Z Gastroenterol. p. 39.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>HZ</given-names></name><name><surname>Wu</surname><given-names>XW</given-names></name><name><surname>Xu</surname><given-names>XB</given-names></name><etal/></person-group><article-title>Evaluating the clinical effect and quality of life in the elderly with functional bowel disorders after treatment with pinaverium bromide</article-title><source>J Clin Rehabil Tissue Eng Res</source><year>2007</year><volume>11</volume><issue>12</issue><fpage>2275</fpage><lpage>2278</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Ihunnaya</surname><given-names>OF</given-names></name><etal/></person-group><article-title>Quality of life in persons with irritable bowel syndrome</article-title><source>Dig Dis Sci</source><year>1998</year><volume>43</volume><issue>2</issue><fpage>400</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1023/A:1018831127942</pub-id><pub-id pub-id-type="pmid">9512138</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winsemius</surname><given-names>A</given-names></name><name><surname>Meuwsen</surname><given-names>IM</given-names></name><name><surname>Boon</surname><given-names>C</given-names></name><etal/></person-group><article-title>A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine</article-title><source>Int J Clin Pract</source><year>2002</year><volume>56</volume><fpage>659</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">12469979</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">MAPI Research Trust. <ext-link ext-link-type="uri" xlink:href="http://www.mapi-trust.org">http://www.mapi-trust.org</ext-link>.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Morris</surname><given-names>CB</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment</article-title><source>Am J Gastroenterol</source><year>2007</year><volume>102</volume><fpage>1442</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01283.x</pub-id><pub-id pub-id-type="pmid">17509027</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Draft guidance for industry on irritable bowel syndrome&#x02014;clinical evaluation of products for treatment: availability. Federal Register. 2010;75(55):13765&#x02013;6.</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bijkerk</surname><given-names>CJ</given-names></name><name><surname>de Wit</surname><given-names>NJ</given-names></name><name><surname>Muris</surname><given-names>JWM</given-names></name><etal/></person-group><article-title>Outcome measures of irritable bowel syndrome: comparison of psychometric and methodological characteristics</article-title><source>Am J Gastroenterol</source><year>2003</year><volume>98</volume><issue>1</issue><fpage>122</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2003.07158.x</pub-id><pub-id pub-id-type="pmid">12526947</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Par&#x000e9;</surname><given-names>P</given-names></name><name><surname>Gray</surname><given-names>J</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Health-related quality of life, work productivity, and health care utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study</article-title><source>Clin Ther</source><year>2006</year><volume>28</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2006.10.010</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>SM</given-names></name><name><surname>Stason</surname><given-names>WB</given-names></name><name><surname>Legedza</surname><given-names>A</given-names></name><etal/></person-group><article-title>The placebo effect in irritable bowel syndrome trials: a meta-analysis</article-title><source>Neurogastroenterol Motil.</source><year>2005</year><volume>17</volume><issue>3</issue><fpage>332</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2982.2005.00650.x</pub-id><pub-id pub-id-type="pmid">15916620</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>EJ</given-names></name><name><surname>Whitehead</surname><given-names>WE</given-names></name><name><surname>Chey</surname><given-names>WD</given-names></name><etal/></person-group><article-title>Design of treatment trials for functional gastrointestinal disorders</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1538</fpage><lpage>1551</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2005.11.058</pub-id><pub-id pub-id-type="pmid">16678567</pub-id></element-citation></ref></ref-list></back></article>